Literature DB >> 26088723

Associations of hippocampal metabolism and regional brain grey matter in neuroleptic-naïve ultra-high-risk subjects and first-episode schizophrenia.

Igor Nenadic1, Raka Maitra2, Soumyajit Basu2, Maren Dietzek2, Nils Schönfeld2, Carsten Lorenz2, Alexander Gussew3, G Paul Amminger4, Patrick McGorry4, Jürgen R Reichenbach3, Heinrich Sauer2, Christian Gaser5, Stefan Smesny2.   

Abstract

Hippocampal pathology has been shown to be central to the pathophysiology of schizophrenia and a putative risk marker for developing psychosis. We applied both (1)H MRS (proton magnetic resonance spectroscopy) at 3Tesla and voxel-based morphometry (VBM) of high-resolution brain structural images in order to study the association of the metabolites glutamate (Glu) and N-acetyl-aspartate (NAA) in the hippocampus with whole-brain morphometry in 31 persons at ultra-high-risk for psychosis (UHR), 18 first-episode schizophrenia patients (Sz), and 42 healthy controls (all subjects being neuroleptic-naïve). Significantly diverging associations emerged for UHR subjects hippocampal glutamate showed positive correlation with the left superior frontal cortex, not seen in Sz or controls, while in first-episode schizophrenia patients a negative correlation was significant between glutamate and a left prefrontal area. For NAA, we observed different associations for left prefrontal and caudate clusters bilaterally for both high-risk and first-episode schizophrenia subjects, diverging from the pattern seen in healthy subjects. Our results suggest that associations of hippocampal metabolites in key areas of schizophrenia might vary due to liability to or onset of the disorder.
Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Magnetic resonance spectroscopy (MRS); Prefrontal cortex (PFC); Psychosis; Schizophrenia; Voxel-based morphometry (VBM)

Mesh:

Substances:

Year:  2015        PMID: 26088723     DOI: 10.1016/j.euroneuro.2015.05.005

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

Review 1.  Stress during critical periods of development and risk for schizophrenia.

Authors:  Felipe V Gomes; Xiyu Zhu; Anthony A Grace
Journal:  Schizophr Res       Date:  2019-01-30       Impact factor: 4.939

2.  Evidence for regional hippocampal damage in patients with schizophrenia.

Authors:  Sadhana Singh; Subash Khushu; Pawan Kumar; Satnam Goyal; Triptish Bhatia; Smita N Deshpande
Journal:  Neuroradiology       Date:  2017-12-11       Impact factor: 2.804

3.  Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study.

Authors:  Nina Vanessa Kraguljac; David Matthew White; Nathan Hadley; Jennifer Ann Hadley; Lawrence Ver Hoef; Ebony Davis; Adrienne Carol Lahti
Journal:  Schizophr Bull       Date:  2016-02-12       Impact factor: 9.306

4.  Add-On MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis- the AMEND Trial Protocol.

Authors:  Katharina O Sandström; Olga B Baltzersen; Anouk Marsman; Cecilie K Lemvigh; Vincent O Boer; Kirsten B Bojesen; Mette Ø Nielsen; Henrik Lundell; Daban K Sulaiman; Mikkel E Sørensen; Birgitte Fagerlund; Adrienne C Lahti; Warda T Syeda; Christos Pantelis; Esben T Petersen; Birte Y Glenthøj; Hartwig R Siebner; Bjørn H Ebdrup
Journal:  Front Psychiatry       Date:  2022-05-20       Impact factor: 5.435

5.  An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS.

Authors:  Lawrence S Kegeles; Adam Ciarleglio; Pablo León-Ortiz; Francisco Reyes-Madrigal; Jeffrey A Lieberman; Gary Brucato; Ragy R Girgis; Camilo de la Fuente-Sandoval
Journal:  Schizophr Res       Date:  2019-09-12       Impact factor: 4.939

6.  Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.

Authors:  Matthijs G Bossong; Mathilde Antoniades; Matilda Azis; Carly Samson; Beverley Quinn; Ilaria Bonoldi; Gemma Modinos; Jesus Perez; Oliver D Howes; James M Stone; Paul Allen; Philip McGuire
Journal:  JAMA Psychiatry       Date:  2019-02-01       Impact factor: 21.596

Review 7.  Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies.

Authors:  Tomomi Nakahara; Sakiko Tsugawa; Yoshihiro Noda; Fumihiko Ueno; Shiori Honda; Megumi Kinjo; Hikari Segawa; Nobuaki Hondo; Yukino Mori; Honoka Watanabe; Kazuho Nakahara; Kazunari Yoshida; Masataka Wada; Ryosuke Tarumi; Yusuke Iwata; Eric Plitman; Sho Moriguchi; Camilo de la Fuente-Sandoval; Hiroyuki Uchida; Masaru Mimura; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2021-09-28       Impact factor: 15.992

8.  Medial Prefrontal Cortex Glutamate Is Reduced in Schizophrenia and Moderated by Measurement Quality: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.

Authors:  Jason Smucny; Cameron S Carter; Richard J Maddock
Journal:  Biol Psychiatry       Date:  2021-06-12       Impact factor: 12.810

Review 9.  Structural and functional imaging markers for susceptibility to psychosis.

Authors:  Christina Andreou; Stefan Borgwardt
Journal:  Mol Psychiatry       Date:  2020-02-17       Impact factor: 15.992

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.